H52 IBV vaccine with heterologous spike protein

A method for immunizing a subject, comprising:

• administering to the subject an immunogenic composition comprising a recombinant IBV comprising an H52 IBV backbone having at least 95% sequence identity to SEQ ID NO:
• 78 and a heterologous IBV S protein or fragment thereof,
• wherein the heterologous IBV S protein is from a different genotype or serotype than the H52 IBV and replaces the homologous H52 IBV S protein or fragment thereof,
• wherein the heterologous IBV S protein or fragment thereof is of a non-Massachusetts genotype or serotype,
• wherein the heterologous IBV S protein or fragment thereof comprises an amino acid sequence having at least 90% sequence identity to at least one of SEQ ID NOs:
• 5, 6, 9, 10, 11, 12, 13, 14, 15, or 16 wherein the heterologous IBV S protein or fragment thereof comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:
• 7 or 8, and
• wherein the heterologous IBV S protein or fragment thereof has a length of at least 1000 amino acids.

An immunogenic composition comprising a recombinant IBV comprising an H52 IBV backbone having at least 95% sequence identity to SEQ ID NO:

• 78 and a heterologous IBV S protein or fragment thereof,
• wherein the heterologous IBV S protein is from a different genotype or serotype than the H52 IBV and replaces the homologous H52 IBV S protein or fragment thereof, and
• wherein the heterologous IBV S protein or fragment thereof is of a non-Massachusetts genotype or serotype, and
• wherein the heterologous IBV S protein or fragment thereof comprises an amino acid sequence having at least 90% sequence identity to at least one of SEQ ID NOs:
• 5, 6, 9, 10, 11, 12, 13, 14, 15, or 16 or wherein the heterologous IBV S protein or fragment thereof comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:
• 7 or 8
• wherein the heterologous IBV S protein or fragment thereof has a length of at least 1000 amino acids.

A recombinant, infectious bronchitis virus (IBV) comprising an H52 IBV backbone and a heterologous IBV spike protein (S protein) or fragment thereof,

• wherein the heterologous IBV S protein is from a different genotype or serotype than the H52 IBV and replaces the homologous H52 IBV S protein or fragment thereof,
• wherein the heterologous IBV S protein or fragment thereof is of a non-Massachusetts genotype or serotype,
• wherein the heterologous IBV S protein or fragment thereof comprises an amino acid sequence having at least 90% sequence identity to at least one of SEQ ID NOs:
• 5, 6, 7, 8,
• wherein the heterologous IBV S protein or fragment thereof has a length of at least 1000 amino acids,
• wherein the heterologous IBV S protein or fragment thereof is from an IBV with a genotype or serotype selected from the group consisting of 4/91 and QX, and
• wherein administration of the immunogenic composition to an animal results in 82-100% protection against challenge with a spike-homologous challenge strain.